ArticleThe lancet. Diabetes & endocrinology2015
Interleukin-1 receptor antagonist: friend or foe to the heart?
Article in The lancet. Diabetes & endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Neutrophil death pathways in myocardial infarction: the balance between injury and repair.Frontiers in immunology · 2026Review
- Role of interleukins in the pathogenesis of coronary heart disease: A literature review.World journal of cardiology · 2025Review
- Neuroprotective effects of gemfibrozil in neurological disorders: Focus on inflammation and molecular mechanisms.CNS neuroscience & therapeutics · 2024Review
- Article
- Characterisation of cytotoxicity and immunomodulatory effects of glycolipid biosurfactants on human keratinocytes.Applied microbiology and biotechnology · 2023Article
- Apolipoprotein B and interleukin 1 receptor antagonist: reversing the risk of coronary heart disease.Frontiers in endocrinology · 2023Article
- Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study.Journal of neuroinflammation · 2022Article
- Peptide-Based HDL as an Effective Delivery System for Lipophilic Drugs to Restrain Atherosclerosis Development.International journal of nanomedicine · 2022Article
- Proteomic and Metabolomic Characterization of Metabolically Healthy Obesity: A Descriptive Study from a Swedish Cohort.Journal of obesity · 2021Article
- Higher circulating omentin is associated with increased risk of primary cardiovascular events in individuals with diabetes.Diabetologia · 2020Article
- Adiponectin, biomarkers of inflammation and changes in cardiac autonomic function: Whitehall II study.Cardiovascular diabetology · 2017Article
- Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?British journal of pharmacology · 2017Review
- From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.Circulation research · 2016Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
25726325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.